Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting

- Clinical Data Utilizing Clearside’s Suprachoroidal Delivery Technology to be Featured in Multiple Oral and Poster Presentations -

ALPHARETTA, Ga., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS), announced today that multiple oral and poster presentations will be delivered at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting taking place November 3 – 6, 2023 in San Francisco, CA. AAO is the world's largest association of eye physicians and surgeons.

Presentations will be delivered by leading physicians on behalf of Clearside and the Company’s commercial and development partners:

Title: Safety and Tolerability of Suprachoroidal CLS-AX (Axitinib Injectable Suspension) in nAMD Patients in a Phase 1/2A Study, OASIS
Presenter: Rahul N. Khurana, M.D.
Session: PO514 - Scientific Poster
Date/Time: On Demand

Title: Experience With Triamcinolone Acetonide Suprachoroidal Injection for Uveitic Macular Edema: A Physician Survey
Presenter: Michael A. Singer, M.D.
Session: PO603 - Scientific Poster
Date/Time: On Demand

Title: ALTITUDE: Suprachoroidal Delivery of ABBV-RGX-314 Investigational Gene Therapy for Diabetic Retinopathy
Presenter: Mark R. Barakat M.D.
Session: RET10 Section VIII: Late Breaking Developments, Part I
Date/Time: Friday, November 3, 2023; 3:53 pm PT

Title: ALTITUDE: A Phase 2 Dose-Escalation Study Evaluating Suprachoroidal Delivery of RGX-314 Gene Therapy for Diabetic Retinopathy
Presenter: Arshad M. Khanani, M.D.
Session: PA051
Date/Time: Sunday, Nov 5, 2023; 4:09 pm PT

Title: A Phase 2 Trial of Belzupacap Sarotalocan, a Targeted Investigational Therapy for Choroidal Melanoma via Suprachoroidal Administration
Presenter: Carol L. Shields, M.D.
Session: PA069
Date/Time: Monday, November 6, 2023; 11:54 am PT

About Clearside’s Suprachoroidal Space (SCS) Injection Platform and SCS Microinjector

Clearside’s patent protected, proprietary suprachoroidal space (SCS) injection treatment approach offers unprecedented access to the back of the eye, where sight-threatening disease often occurs. The Company’s unique platform is inherently flexible and intended to work with established and new formulations of medications. Clearside’s patented SCS Microinjector can deliver a wide variety of drug candidates into the suprachoroidal space, providing targeted delivery to potentially improve efficacy and compartmentalization of medication to reduce or eliminate toxic effects on non-diseased cells. The SCS Microinjector system comprises a syringe, a custom-designed hub, and two 30-gauge hollow microneedles of varying lengths, each less than 1.2 millimeters, optimizing insertion and suprachoroidal administration of drugs.